Protalix Biotherapeutics is a biotechnology business based in the US. Protalix Biotherapeutics shares (PLX) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $3.00 – an increase of 5.26% over the previous week. Protalix Biotherapeutics employs 213 staff and has a trailing 12-month revenue of around $53.4 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.00 |
|---|---|
| 52-week range | $0.82 - $3.10 |
| 50-day moving average | $2.51 |
| 200-day moving average | $1.75 |
| Wall St. target price | $14.50 |
| PE ratio | 75 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.04 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3 from 2025-05-02
| 1 week (2025-04-25) | 5.26% |
|---|---|
| 1 month (2025-04-04) | 25.52% |
| 3 months (2025-02-05) | 12.36% |
| 6 months (2024-11-05) | 130.77% |
| 1 year (2024-05-03) | 163.16% |
|---|---|
| 2 years (2023-05-04) | -10.71% |
| 3 years (2022-05-04) | 158.62% |
| 5 years (2020-05-04) | 3.08 |
Valuing Protalix Biotherapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Protalix Biotherapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Protalix Biotherapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 75x. In other words, Protalix Biotherapeutics shares trade at around 75x recent earnings.
Protalix Biotherapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.2 million.
The EBITDA is a measure of a Protalix Biotherapeutics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $53.4 million |
|---|---|
| Operating margin TTM | 39.57% |
| Gross profit TTM | $29.1 million |
| Return on assets TTM | 3.1% |
| Return on equity TTM | 7.64% |
| Profit margin | 5.49% |
| Book value | $0.57 |
| Market Capitalization | $237.6 million |
TTM: trailing 12 months
We're not expecting Protalix Biotherapeutics to pay a dividend over the next 12 months.
Protalix Biotherapeutics's shares were split on a 1:10 basis on 19 December 2019 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Protalix Biotherapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Protalix Biotherapeutics shares which in turn could have impacted Protalix Biotherapeutics's share price.
Over the last 12 months, Protalix Biotherapeutics's shares have ranged in value from as little as $0.8214 up to $3.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Protalix Biotherapeutics's is 0.456. This would suggest that Protalix Biotherapeutics's shares are less volatile than average (for this exchange).
Protalix BioTherapeutics, Inc. , a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S. p. A.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .